David S. Silberstein - 19 Sep 2025 Form 4 Insider Report for Lantern Pharma Inc. (LTRN)

Role
Director
Signature
/s/ David S. Silberstein
Issuer symbol
LTRN
Transactions as of
19 Sep 2025
Net transactions value
$0
Form type
4
Filing time
23 Sep 2025, 16:05:09 UTC
Previous filing
17 Jul 2024
Next filing
13 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Silberstein David S. Director 1920 MCKINNEY AVENUE, 7TH FLOOR, DALLAS /s/ David S. Silberstein 22 Sep 2025 0001812659

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LTRN Stock Option (Right to Buy) Disposed to Issuer $0 -9,135 -100% $0.000000 0 15 Jun 2020 Common Stock 9,135 $15.00 Direct F1
transaction LTRN Stock Option (Right to Buy) Award $0 +9,135 $0.000000 9,135 15 Jun 2020 Common Stock 9,135 $5.04 Direct F1
transaction LTRN Stock Option (Right to Buy) Disposed to Issuer $0 -3,200 -100% $0.000000 0 04 Nov 2021 Common Stock 3,200 $10.32 Direct F2
transaction LTRN Stock Option (Right to Buy) Award $0 +3,200 $0.000000 3,200 04 Nov 2021 Common Stock 3,200 $5.04 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and provides for vesting in equal monthly increments over a 36-month period commencing July 15, 2020.
F2 The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on November 4, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing December 4, 2021.